Apnimed
Cambridge, Massachusetts, United States · Healthcare, Manufacturing
Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea – patients with obstructive sleep apnea could benefit from treatment with a safe and effective oral medication dosed once daily at bedtime. Apnimed’s lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep. Based
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- 82
- Industries
- Healthcare, Manufacturing
- Status
- Public (APMD)
- Website
- apnimed.com
- Company page
Recent activity at Apnimed
- : SEC 8-K (4.02): On November 13, 2026, the Audit Committee of Apnimed, Inc. determined that the company's previously issued financial statements for the three and six months ended June 30, 2026, should no longer be relied upon due to a misclassification error regarding a $85.4 million gain from the disposition of its interest in Shionogi-Apnimed Sleep Science, LLC. The gain, which should have been classified under discontinued operations, was incorrectly reported as part of continuing operations. While the misstatement does not affect overall revenue or net income, it requires a restatement of financial results from those periods, impacting disclosures in the company's previous reports to the SEC. The company is taking steps to correct this classification error, highlighting the importance of accurate financial reporting.
- : Apnimed Inc. Appoints Kevin Lind as Chief Executive Officer
- : Apnimed
- : Apnimed
- : Apnimed
- : Apnimed acquires global rights to sulthiame
- : Apnimed
- : Apnimed, Inc. Appoints Ramzi Benamar as Chief Financial Officer
- : Apnimed Announces New Leadership Appointments as the Company Builds Its Commercial and Human Resource Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
- : Apnimed Completes Oversubscribed $79.75 Million Series C Extension Financing To Fund Two Planned Phase 3 Trials Of Ad109, An Oral Medication With The Potential To Be The First Therapy For Direct Treatment Of Obstructive Sleep Apnea (Osa)
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Apnimed funding history
| Date | Round | Amount |
|---|---|---|
| Mar 2026 | Debt Financing | $150.0M |
| Sep 2025 | Venture | $23.0M |
| Apr 2025 | Venture | $16.5M |
| Jan 2023 | Series C | $79.8M |
| Dec 2022 | Venture | $79.7M |
Leadership
- Joseph Avellone, Director
- Gerald Chan, Director
- Ron Farquhar, Director
- Dennis Molnar, Executive Officer, Director
- Lawrence Miller, Executive Officer, Director
Verified email and direct lines for Apnimed’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Apnimed files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Apnimed in the news
- FDA Accepts NDA for Apnimed’s AD109 for the Treatment of Obstructive Sleep Apnea - NeurologyLive (Jul 15, 2026)
- Apnimed Submits NDA for AD109 Following Positive Phase 3 Results in Obstructive Sleep Apnea - Pharmacy Times (Jun 03, 2026)
- Apnimed shares positive results in clinical trial of sleep apnea drug - American Academy of Sleep Medicine | AASM (May 23, 2025)
- A 'Holy Grail' Sleep Apnea Pill Could Be On The Market Next Year - Forbes (Jan 12, 2026)
- Apnimed Announces Upcoming Oral Presentation at SLEEP 2026 to Highlight Pooled Phase 3 Data for AD109 in Obstructive Sleep Apnea - PR Newswire (Jun 10, 2026)
- Investigational AD109 Meets End Points in Phase 3 LunAIRo Trial, Eyeing FDA Submission for Obstructive Sleep Apnea - NeurologyLive (Jul 23, 2025)
- Apnimed Announces Pricing of Upsized Initial Public Offering - PR Newswire (Jul 30, 2026)
- Apnimed Announces Positive Topline Results in the First Landmark Phase 3 Clinical Trial of AD109, an Investigational Once-daily Oral Pill for Obstructive Sleep Apnea - PR Newswire (May 19, 2025)
Companies similar to Apnimed
- InspireMD · Healthcare, Manufacturing
- Ascendia Pharmaceuticals · Healthcare, Manufacturing
- Spineology · Healthcare, Manufacturing
- Cala Health · Healthcare, Manufacturing
- Ionetix Corp · Healthcare, Manufacturing
About Apnimed: questions and answers
What does Apnimed do?
Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea – patients with obstructive sleep apnea could benefit from treatment with a safe and effective oral medication dosed once daily at bedtime. Apnimed’s lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep. Based
Where is Apnimed headquartered?
Apnimed is headquartered in Cambridge, Massachusetts, United States.
How many employees does Apnimed have?
Apnimed has about 82 employees.
Has Apnimed raised funding?
Yes. Fundz has recorded 5 funding events for Apnimed. The most recent, Debt Financing of $150.0M, was in Mar 2026.
What is the latest news on Apnimed?
On Nov 13, 2026, SEC 8-K (4.02): On November 13, 2026, the Audit Committee of Apnimed, Inc. determined that the company's previously issued financial statements for the three and six months ended June 30, 2026, should no longer be relied upon due to a misclassification error regarding a $85.4 million gain from the d
Is Apnimed a public company?
Yes. Apnimed is publicly traded under the ticker APMD.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy